INS and diabetes mellitus: Long-term simulated costs of treatment related to chronic complications of diabetes are shown in Table 7, and except for costs of background treatment and lower extremity disease treatment, costs of treatment related to chronic complications were lower in the IDegLira than in the GLP-1RA+basal insulin group.